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Background: Recent advances in surgical techniques and perioperative management have led to improved
surgical outcomes, especially perioperative outcomes. The aim of this study was to review our experience with
hepatic resection for hepatocellular carcinoma (HCC) over a ten-year period to determine how to improve
long-term surgical outcomes.
Methods: From January 1996 to December 2007, 610 patients underwent curative resection for HCC at Yonsei
University Health System, Seoul, Korea. Prognostic factors for disease-free and overall survival were identified, and
surgical outcomes were compared between two time periods: before 2003 and after 2003.
Results: The 1-, 3-, and 5-year overall survival rates were 90.1%, 74.9% and 64.4%, respectively. The patients after
2003 tended to have improved overall survival. The survival rate after recurrence in patients with tumors > 3 cm
was significantly greater after 2003. (P = 0.044).
Conclusions: The improved survival rates after 2003 may be explained by better selection of surgical candidates, a
reduced perioperative transfusion rate due to improved surgical techniques, and active multimodal treatment for
recurrent HCC.
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The first successful liver resection was performed by Dr.
Langenbuch in 1886 [1], but over the next 100 years, the
surgical outcomes of liver resection improved only grad-
ually. Until 1980, the hospital mortality rate could reach
33% after major hepatic resection, and operative death
could exceed 15% [2].
However, recent advances in surgical techniques and
perioperative management have led to improved surgical
outcomes, especially perioperative outcomes. Some stud-
ies have reported that operative mortality and overall
and disease-free survival rates have improved over the
past two decades [3].
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unless otherwise stated.(HCC) over a ten-year period to determine how to im-
prove long-term surgical outcomes by analyzing the im-
pact of prognostic factors and active treatment for
recurrent-HCC patients in two different time periods.Methods
Patients
From January 1996 to December 2007, a total of 610
consecutive patients underwent curative liver resection
for HCC at Yonsei University College of Medicine,
Seoul, Korea. Curative resection was defined as complete
removal of the tumor with a clear microscopic margin.
All patients underwent pre-operative liver biochemistry
tests and Child-Pugh grading. Surgical treatment was
performed primarily in patients classified as Child-Pugh
A; of the 610 patients, only 6 were Child-Pugh B
(Table 1). The extent of resection was determined ac-
cording to liver function such as the result of indocya-
nine green retention rate at 15 minutes (ICG R15),
Child-Pugh classification, Clinical portal hypertension. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the 610 patients who received
curative resection for hepatocellular carcinoma
Age (range) 53.36 ± 10.09 (22 to 81)








A/B 604 (99.0%)/6 (1.0%)
Cirrhosis 318 (52.1%)
Serum albumin (g/dL) 4.07 ± 0.51 (2.20 to 3.40)
AST (IU/L) 41.93 ± 28.80 (10 to 321)
ALT (IU/L) 42.30 ± 37.16 (3 to 425)
Operation
minor/major 319 (52.3%)/291 (47.7%)
Perioperative bleeding
≤ 1,000 cc/>1,000 cc 426 (69.8%)/184 (30.2%)
Perioperative transfusion 267 (43.8%)
Perioperative complication 169 (27.7%)
Perioperative mortality 12 (1.9%)
Resection margin
≤ 1 cm/>1 cm 235 (38.5%)/356 (58.4%)
Tumor size (cm) 4.64 ± 2.81 (0.2 to 18.0)
Histologic differentiation
Edmondson-Steiner grade I to II 358 (58.7%)
Edmondson-Steiner grade III to IV 156 (25.6%)
AFP (IU/mL) 2,541.38 ± 8,750.95 (0.46 to 83000.00)
Multiple tumors 122 (20.0%)
Gross vascular invasion 46 (7.5%)
Microscopic vascular invasion 304 (49.8%)
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus.
Figure 1 Classification of patients for the study. Patients were
first divided into two groups according to the period of liver
resection (group A: before 2003; group B: after 2003). Patients were
then divided into two groups according to tumor size (group A3:
larger than 3 cm; group B: smaller than 3 cm).
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bocytopenia and esophageal varix as well as gross find-
ings of the liver during laparotomy. If ICG R15 was less
than 10%, more than a right lobectomy was considered
to be acceptable [4]. At our hospital, a tumor was con-
sidered resectable if there was no extrahepatic metastasis
on preoperative imaging studies, no evidence of tumor
thrombosis in major vessels such as the main portal vein
or inferior vena cava, and if adequate tumor-free mar-
gins and sufficient remnant liver volumes were secured.
Perioperative mortality was defined as death in the hos-
pital after hepatectomy during the first admission for
liver resection. Any complication requiring medicationor an interventional procedure was considered peri-
operative morbidity.
In 2003, our hospital established a Liver Cancer
Special Clinic where hepatic surgeons, hepatologists,
diagnostic radiologists, interventional radiologists, and
radiation oncologists would meet once a week to discuss
how to treat patients newly diagnosed with HCC and
those with recurrent HCC. Since we expected that these
multilateral diagnoses and treatment services would pro-
vide more effective treatment for HCC patients, we cate-
gorized patients in the current study according to the
period of liver resection: before 2003, group A (n = 233),
and after 2003, group B (n = 377). In a preliminary study,
we also found that the overall survival of patients with
tumors larger than 3 cm was greater after 2003 than be-
fore 2003. Thus, we also dichotomized patients with a
tumor size above 3 cm according to the period of liver
resection: before 2003, group A3 (n = 163), and after
2003, group B3 (n = 230, Figure 1).
Each patient was screened postoperatively for tumor
markers, such as alpha-fetoprotein (AFP) and protein-
induced vitamin K absence or antagonist II (PIVKA-II),
and underwent ultrasonography or a dynamic computed
tomography scan one month after surgery and every three
months thereafter. The median follow-up time after resec-
tion was 52 months (range: 0 to 152 months). If tumors
recurred, appropriate treatment was initiated according to
the number, size, and location of the tumors.
Analysis of prognostic factors for disease-free and overall
survival
Prognostic factors for disease-free and overall survival
were investigated through 18 clinicopathologic variables,
including patient-, surgical-, and tumor-related variables.
Patient- related variables were age, sex, serum albumin,
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ferase (AST), platelet count, and liver cirrhosis. Surgical
variables were perioperative transfusion, amount of in-
traoperative bleeding, perioperative morbidity, surgical-free
margin, and extent of resection. The extent of resection
was determined according to Couinaud’s classification: a
major resection was defined as a resection of three or
more segments, and a minor resection, as a resection of
two or fewer segments [5]. Tumor -related variables were
tumor size, macroscopic vascular invasion, microscopic
vascular invasion, histologic differentiation of the tumor
by the Edmondson-Steiner grade, serum alpha-fetoprotein
level, and multiplicity of tumors. Tumor size was classified
into two groups: the patients with tumor less than or
equal to 3 cm and those with tumor size greater than
3 cm. In cases of multiple tumors, the largest diameter of
the main mass was considered to be the tumor size.
Multiple tumors were defined as tumors with hepatic
satellitosis, multifocal tumors, or intrahepatic metastases
according to the seventh AJCC [6].
Statistical analysis
Continuous data were analyzed with Student’s t-tests
and presented as mean and standard deviation. Categor-
ical variables were compared with χ2 tests or Fisher
exact tests, as appropriate. Survival curves were obtained
by the Kaplan-Meier method, and differences in survival
between groups were compared with the log rank test.
The 18 clinicopathologic variables were dichotomized
and analyzed in relation to their effects on disease-free
and overall survival after resection. Perioperative mortal-
ities were included in the overall survival analysis but ex-
cluded from the disease-free survival analysis. After
univariate analysis of the factors affecting survival, only
the significant variables were used in the multivariable
analysis with the Cox-proportional hazards model with
the forward stepwise logistic regression model. Statistical
analyses were performed with SPSS 18 for Windows
(SPSS Inc, Chicago, IL, USA). A value of P < 0.05 was
considered statistically significant.
Results
Clinicopathological features of all patients
Four hundred and eighty of 610 patients were men
(78.7%). The most common underlying liver disease was
hepatitis B viral infection (n = 476, 78.0%). The majority
of patients had relatively good liver function: most were
Child-Pugh class A with mean values of serum albumin,
AST, and ALT in the normal range. More than half of
patients had liver cirrhosis on histologic examination
after operation (n = 318, 52.1%), and the mean tumor
size was 4.64 cm (0.2 cm to 18.0 cm). One fifth of pa-
tients had multiple tumors (n = 122, 20.0%). About half
of patients (n = 291, 47.7%) had undergone major liverresection. The amount of perioperative bleeding was
below 1,000 cc in 436 patients (69.8%). The major cause
of excessive perioperative bleeding was major liver resec-
tion (P = 0.014). There were 169 patients with periopera-
tive complications (27.7%) and 12 with perioperative
mortality (1.9%). Three hundred and fifty-six patients
(58.4%) had a resection margin greater than 1 cm. On
histopathologic examination, 358 patients had well- to
moderate-differentiation (58.7%), 46 patients had gross
vascular invasion (7.5%), and 304 patients had micro-
scopic vascular invasion (49.8%) (Table 1).
Prognostic factors for disease-free and overall survival of
all patients
The 1-, 3-, and 5-year disease-free survival rates were
71.7%, 52.7%, and 45.8% (n = 598), respectively; the over-
all survival rates were 90.1%, 74.9%, and 64.4% (n = 610),
respectively. Multivariable analysis revealed that AST
(>50 IU/L), liver cirrhosis, perioperative transfusion, mul-
tiple tumors, microvascular invasion, and Edmondson-
Steiner grade III to IV were independent adverse prognostic
factors for disease-free survival; while serum albumin
(≤3.5 g/dL), low platelet count (≤100,000 mm3), peri-
operative transfusion, perioperative morbidity, tumor size
larger than 3 cm, multiple tumors, macrovascular inva-
sion, and Edmondson-Steiner grade III to IV were inde-
pendent adverse prognostic factors for overall survival
(Table 2). Thus, perioperative transfusion, liver cirrhosis,
and Edmondson-Steiner grade III to IV were adverse
prognostic factors for both disease-free and overall
survival.
Disease-free and overall survival in relation to the period
of hepatic resection
Neither disease-free nor overall survival differed signifi-
cantly between groups (disease-free: P = 0.616; overall: P =
0.098). Nonetheless, there was a marked difference in
overall survival between groups until 72 months; the 1-,
3-, and 5-year overall survival rates of the patients in
group A were 87.1%, 69.5%, and 60.5%, respectively,
whereas those of the patients in group B were 92.0%,
78.3%, and 66.4%, respectively (P = 0.098). Patients in
group B were significantly older and had a greater inci-
dence of liver cirrhosis, major resection, and surgical re-
section margin longer than 1 cm. Patients in group A had
a greater incidence of low albumin, perioperative transfu-
sion, minor resection, tumor size larger than 3 cm,
multiple tumors, microvascular invasion, and Edmondson-
Steiner grade III to IV.
Overall survival after recurrence of HCC
Since overall survival tended to be greater in group B,
the data for patients with recurrent HCC after liver re-
section were further evaluated. During the follow-up
Table 2 Independent prognostic factors for disease-free and overall survival by multivariate analysis
Variable Coefficient Standard error P-value Relative risk (95% CI)
Disease-free survival
AST (>50 IU/L) 0.381 0.136 0.016 1.379 (1.062 to 1.789)
Liver cirrhosis 0.296 0.119 0.043 1.292 (1.009 to 1.654)
Perioperative transfusion 0.301 0.118 0.008 1.386 (1.090 to 1.763)
Multiple tumors 0.553 0.134 0.013 1.564 (1.097 to 2.230)
Microvascular invasion 0.382 0.128 < 0.001 1.604 (1.255 to 2.050)
Edmondson-Steiner grade III to IV 0.321 0.131 0.014 1.379 (1.066 to 1.784)
Overall survival
Serum albumin (≤3.5 g/dL) 0.587 0.166 < 0.001 1.798 (1.298 to 2.490)
Platelet count (≤100,000/mm3) 0.442 0.167 0.008 1.557 (1.122 to 2.161)
Perioperative transfusion 0.477 0.140 0.001 1.610 (1.224 to 2.118)
Perioperative morbidity 0.353 0.143 0.013 1.423 (1.076 to 1.883)
Tumor size (>3 cm) 0.313 0.154 0.043 1.367 (1.010 to 1.850)
Multiple tumors 0.679 0.147 < 0.001 1.973 (1.478 to 2.633)
Macrovascular invasion 0.581 0.227 0.011 1.789 (1.145 to 2.793)
Edmondson-Steiner grade III to IV 0.419 0.147 0.004 1.521 (1.141 to 2.028)
AST, aspartate aminotransferase; CI, confidence interval.
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The 1-, 3-, and 5-year overall survival rates after recur-
rence were 74.6%, 50.7%, and 34.0%, respectively. Of the
299 patients with tumor recurrence, 282 underwent
treatment for recurrence; the most commonly per-
formed treatment was transarterial chemoembolization
(TACE, 58.1%). More than 80% of deaths were due to
tumor recurrence (Table 3). In addition, the 1-, 3-, and
5-year overall survival rates of patients with recurrent
HCC were significantly lower before 2003 than after
2003 (P = 0.044). Specifically, the 1-, 3-, and 5-yearTable 3 Recurrence of hepatocellular carcinoma and
death after curative resection
Recurrence
Intrahepatic recurrence 222 (76.6%)
Extrahepatic recurrence 68 (23.4%)
Main treatment for recurrence
Transplantation 10 (3.4%)
Repeat resection 29 (9.8%)
Local ablation therapy 29 (9.8%)
TACE 172 (58.1%)
Chemotherapy 26 (4.3%)
Radiation therapy 16 (5.4%)
Cause of death
Recurrent HCC 182 (80.9%)
Complication of liver cirrhosis without recurrence 25 (11.1%)
Unrelated (including perioperative death) 18 (8.0%)
HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.overall survival rates after 2003 were 77.7%, 55.5%, and
39.9%, respectively, while the 1-, 3-, and 5-year overall
survival rates before 2003 were 70.5%, 44.7%, and 28.5%,
respectively.
Overall survival of patients with tumors larger than 3 cm
In a preliminary study, we found no significant differ-
ence in disease-free survival after hepatectomy between
patients with tumors larger than 3 cm and those with tu-
mors smaller than 3 cm; however, overall survival was
significantly lower for patients with tumors larger than
3 cm (P = 0.006). In the current study, there was no im-
provement in disease-free (P = 0.860) or overall survival
(P = 0.224) in patients with tumors smaller than 3 cm
after 2003. In contrast, the overall survival of patients
with tumors larger than 3 cm was significantly improved
after 2003 (P = 0.012, Figure 2a). Moreover, the overall
survival after recurrence in the patients with tumors
larger than 3 cm was significantly improved after 2003
(P = 0,002, Figure 2b). Patients in group A3 were more
likely to have a preoperative serum albumin level lower
than 3.5 g/dL (P < 0.001). Patients in group B3 were
more likely to have had a major operation (P = 0.004).
Perioperative transfusion (P < 0.001) and a safety resec-
tion margin shorter than 1 cm (P < 0.002) were more
common in group A3. Multiple tumors (P = 0.008) and
tumors with microscopic vascular invasion (P = 0.003)
were more common in group A3 (Table 4). Male sex,
serum albumin lower than 3.5 g/dL, liver cirrhosis, peri-
operative transfusion, intraoperative bleeding greater
than 1,000 cc, perioperative complications, multiple
Figure 2 Comparison of overall survival between groups A3 and B3. (a) Overall survival of patients with tumors larger than 3 cm was
significantly improved after 2003 (P = 0.012). (b) The overall survival after recurrence in patients with tumors larger than 3 cm was significantly
improved after 2003 (P = 0.002).
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Table 4 Characteristics of patients with tumors larger than 3 cm
Variables Group A3 (n = 163) Group B3 (n = 230) P-value
Age (range) 51.90 ± 10.14 54.59 ± 9.69 0.008
Gender (male/female) 131/32 (80.4/19.6%) 177/53 (77.0/23.0%) 0.418
Etiology 0.085
HBV 125 (76.7%) 176 (76.5%)
HCV 2 (1.2%) 12 (5.2%)
both 1 (0.6%) 3 (1.3%)
alcohol 7 (4.3%) 3 (1.3%)
idiopathic 28 (17.2%) 36 (15.7%)
Child-Pugh classification 0.653
A/B 160/3 (98.2/1.8%) 228/2 (99.1/0.9%)
Cirrhosis 66 (40.5%) 114 (49.6%) 0.075
Serum albumin≤ 3.5 g/dL 39 (24.1%) 25 (10.9%) < 0.001
AST (IU/L) > 50 31 (19.1%) 56 (24.3%) 0.221
ALT (IU/L) > 50 38 (23.5%) 56 (24.3%) 0.839
Operation 0.004
minor/major operation 87/76 (53.4/46.6%) 89/141 (38.7/61.3%)
Perioperative bleeding 0.131
≤ 1,000 cc/>1,000 cc 103/60 (63.2/36.8%) 162/68 (70.4/29.6%)
Perioperative transfusion 109 (66.9%) 79 (34.3%) < 0.001
Perioperative complication 51 (31.3%) 61 (26.5%) 0.302
Perioperative mortality 5 (3.1%) 5 (2.2%) 0.747
Resection margin 0.002
≤ 1 cm/>1 cm 79/72 (52.3/47.7%) 83/144 (36.6/63.4%)
Histologic differentiation 0.073
Edmondson-Steiner grade III to IV 57 (35.0%) 57 (24.8%)
AFP (IU/mL) 4,129.58 ± 11,213.53 3,086.58 ± 10,003.07 0.334
Multiple tumors 45 (27.6%) 38 (16.5%) 0.008
Gross vascular invasion 10 (6.1%) 22 (9.6%) 0.746
Microscopic vascular invasion 103 (63.2%) 111 (48.3%) 0.003
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus.
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dependent adverse prognostic factors for overall survival
of patients with tumors larger than 3 cm in multivariate
analysis.
Discussion
HCC is one of the most fatal malignant diseases. In
Korea, HCC is the second most common cause of death
from cancer even though it is the fifth most common
newly diagnosed cancer [7]. Hepatic resection is consid-
ered to be the treatment of choice for HCC in patients
with preserved liver function [8]. However, high peri-
operative morbidity and mortality have been major obsta-
cles to overcome. Fortunately, recent advances in surgical
techniques and perioperative management have led to
improved surgical outcomes, especially perioperativeoutcomes [9-11]. Indeed, we observed improved surgical
outcomes in the current study: the rate of perioperative
morbidity was 27.7% and the rate of mortality, 1.9%,
during the last 10 years. Thus, the major concern for re-
searchers and clinicians has shifted from surgical tech-
nique to prognostic factors that predict successful
outcomes. Various prognostic factors have been studied
and are generally classified into three categories: patient,
surgical, and tumor factors [12]. In this study, we investi-
gated 18 prognostic factors, including patients factors
(which are age, gender, serum albumin, ALT, AST, platelet
count, and liver cirrhosis), surgical factors (which are peri-
operative transfusion, perioperative bleeding, perioperative
morbidity, surgical resection margin, and extent of resec-
tion), and tumor factors (which are tumor size, number
of tumors, macroscopic vascular invasion, microscopic
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level). Multivariable analysis revealed that these three fac-
tors each affected the long-term surgical outcomes.
Liver cirrhosis and AST levels, which were independ-
ent prognostic factors for disease-free survival in the
current study, reflect the condition of the liver paren-
chyma around the tumor. Poon et al. [13] analyzed risk
factors in relation to recurrence time after liver resection
for patients with HCC and found that rupture of tumor
and vascular invasion were risk factors for early recur-
rence, whereas liver cirrhosis was a risk factor for late
recurrence. Therefore, the serum AST level, which re-
flects the activity of hepatitis and cirrhosis, might be re-
lated to recurrence by multicentric carcinogenesis rather
than intrahepatic metastasis. Thus, controlling hepatitis
activity and the progression of liver cirrhosis may help
prevent tumor recurrence after liver resection. Mazzafero
et al. [14] reported that interferon may reduce late tumor
recurrence (that is two years after liver resection) in pa-
tients with hepatitis C. Similarly, Lo et al. [15] reported
that patients with predominantly hepatitis B-related HCC
might receive a survival benefit from adjuvant interferon.
However, the study at our institution found that survival
after treatment in patients with late recurrence did not
differ from that of patients without recurrence after liver
resection [16]. These results indicate that early detection
and active treatment for recurrent HCC after liver resec-
tion is effective. This explains why serum AST level and
liver cirrhosis were independent prognostic factors for
disease-free survival, but not for overall survival, after liver
resection.
Perioperative transfusion was an independent prognos-
tic factor for both disease-free and overall survival. A
few previous studies have also reported that HCC often
recurs after perioperative transfusion [17-19]. This rela-
tionship might result from the immune suppressive ef-
fects of transfusion, in which the natural killer cells andFigure 3 The practical strategy to improve long-term surgical outcomlymphokine-activated killer cells are suppressed by re-
duction of IL-2 secretion from T cells [20].
Liver function at operation is closely related to postop-
erative morbidity. Moreover, liver function is also re-
quired to cope with the aggressive treatment required
for HCC recurrence. In the current study, preoperative
serum albumin level and platelet count, which reflect
liver function and severity of liver cirrhosis, were inde-
pendent prognostic factors for overall survival after liver
resection. The 1-, 3-, and 5-year overall survival rates of
the 24 patients with serum albumin levels lower than
3.5 g/dL and platelet counts lower than 100,000 mm3
were 75.0%, 45.1%, and 40.6%, respectively. These rates
were significantly lower than those for patients with
serum albumin levels above 3.5 g/dL and platelet counts
above 100,000 mm3 (90.7%, 76.1%, and 65.8%, respect-
ively; P = 0.001). Thus, minimal resection to preserve the
normal parenchyma of the liver or other treatment
modalities such as percutaneous ablation therapy or
transplantation should be considered for patients with
deteriorated liver function [21].
Multiple tumors, microvascular invasion, and a higher
Edmondson-Steiner grade were independent prognostic
factors for both disease-free and overall survival. These
variables represent the aggressiveness of the tumor.
Large tumor size is a well-known risk factor for recur-
rence after liver resection [18]. According to Shimozawa
et al. [22], survival and recurrence rates in HCC tumors
with a diameter smaller than 3 cm were better than
those for tumors with a diameter larger than 3 cm. Simi-
larly, our results indicate that a tumor size larger than
3 cm was an independent adverse prognostic factor for
overall survival. We also compared the overall survival
after tumor recurrence for patients with tumors larger
than 3 cm in relation to the period of operation. Overall
survival after recurrence was significantly greater for pa-
tients who underwent liver resection after 2003 thanes of hepatocellular carcinoma.
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0.012, Figure 2a). Low serum albumin level, liver cirrho-
sis, perioperative transfusion, perioperative bleeding,
perioperative morbidity, multiple tumors, and poor
histologic grade were independent adverse prognostic
factors for patients with tumors larger than 3 cm. Peri-
operative transfusion and clear resection margin less
than 1 cm were more prevalent before 2003 (Table 4).
The serum albumin level was higher in patients who
underwent liver resection after 2003, which might indi-
cate improvement in patient selection for liver resection.
Perioperative transfusion was performed less frequently
after 2003, although major liver resection was performed
more frequently. These data suggest that surgical tech-
niques had become more refined after 2003. Moreover,
after 2003, our hospital had more effective and appropri-
ate treatment modalities for patients with HCC recur-
rence due to the opening of our Liver Cancer Special
Clinic. Thus, proper selection of surgical patients, ad-
vanced surgical techniques, and active treatment for pa-
tients with recurred HCC may have led to improved
survival after recurrence. However, overall survival after
recurrence in patients with tumors less than 3 cm did
not differ before or after 2003 (P = 0.105). Hence, surgi-
cal technique and active treatment for recurrence may
have a greater effect on the long-term survival of pa-
tients with larger than 3 cm HCC comparing those with
smaller than 3 cm tumors.
Even after curative treatment for HCC, recurrence of
HCC is quite common, with a 5-year recurrence rate
reaching 80 to 90% [23]. In the current study, the 5-year
disease-free survival rate after liver resection was 45.9%,
and the overall survival rate was 64.4%. The majority of
deaths (182 of 225; 80.9%) occurred in patients with recur-
rent HCC. The most common type of recurrence was
intrahepatic recurrence (n = 222, 76.6%, Table 3), which is
consistent with the results of previous studies [18,24-29].
Since this suggests that most deaths were related to recur-
rence after curative resection, it appears that the preven-
tion or treatment of recurrence may improve long-term
surgical outcomes after liver resection. Recent studies
have described different treatments for recurrence, such
as liver transplantation, liver resection, ablative therapy, or
transarterial chemoembolization [22,25-28]. These multi-
modal treatments for recurrence were also performed in
our hospital, and more active and meticulous approaches
were possible after the establishment of the Liver Cancer
Special Clinic in 2003. The 5-year overall survival rates
were about 20% greater than the 5-year disease-free sur-
vival rates in this study. Due to these efforts, the overall
survival after recurrence of HCC was significantly greater
after 2003.
Our study has some limitations. First, the data were
collected retrospectively. Second, although we believethat more active and appropriate treatment for recur-
rence was provided after 2003 by the Liver Cancer Spe-
cial Clinic, there was no unequivocal evidence for this
possibility. Therefore, a randomized controlled trial that
includes the use of a clinical grading system to assess
the activity and appropriateness of treatment for recur-
rence is required.
Conclusions
On the basis of our ten-year experience of liver resection
for HCC, we describe possible strategies to improve
long-term surgical outcome for HCC in Figure 3. In
brief, proper selection of surgical candidates, careful sur-
gery to avoid perioperative bleeding or transfusion, early
detection with active treatment for patients with recur-
rent HCC, and, possibly, postoperative adjuvant therapy
for prevention of intrahepatic metastasis and de novo re-
currence may be the key strategies to improve long-term
survival after liver resection for HCC. Moreover, surgical
treatment and active treatment for recurrence should be
performed in patients with tumors larger than 3 cm.
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